Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mara Hester Rendi"'
Autor:
Megan Burke Fitzpatrick, Mara Hester Rendi, Nancy Barbara Kiviat, Pape Toure, Amadou Dem, Papa Salif Sow, Stephen Edward Hawes, Qinghua Feng, Kimberly Heller Allison
Publikováno v:
The Pan African Medical Journal, Vol 34, Iss 67 (2019)
INTRODUCTION: Breast cancer is among the most common cancers among women in most of Afri-ca. However, features of histologically confirmed breast cancers presenting in specific regional popula-tions is limited. Our study describes the clinic-patholog
Externí odkaz:
https://doaj.org/article/7dc0e80814b7471ab0ea2923078d3022
Autor:
Susan Olet, Tamera J. Lillemoe, Monica Knaack, Michaela L. Tsai, Janet Krueger, Mara Hester Rendi, Erin Grimm, Karen K. Swenson, Rina Yarosh, Barbara Susnik
Publikováno v:
International Journal of Breast Cancer, Vol 2021 (2021)
International Journal of Breast Cancer
International Journal of Breast Cancer
Objectives. The response to HER2-targeted neoadjuvant chemotherapy (NAC) in HER2-positive (+) breast cancer can be quantified using residual cancer burden (RCB) pathologic evaluation to predict relapse free/overall survival. However, more information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b8caed7d09078c1ca882557a4aaa70
Autor:
Erinn Downs-Kelly, Barbara Susnik, Karen K. Swenson, Erin V Grimm, Hadi Yaziji, Kimberly H. Allison, Tamera J. Lillemoe, Janet Krueger, Michaela L. Tsai, Mara Hester Rendi, David G. Hicks
Publikováno v:
Applied immunohistochemistrymolecular morphology : AIMM. 29(9)
OBJECTIVE College of American Pathologists and the American Society of Clinical Oncology guidelines provide straightforward criteria for HER2 interpretation in breast carcinomas; however, a subset of cases present unusual diagnostic dilemmas. MATERIA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fba75422164827447f609dcdf0a1c58
https://pubmed.ncbi.nlm.nih.gov/34282066
https://pubmed.ncbi.nlm.nih.gov/34282066
Autor:
Hadi Yaziji, Erin V Grimm, Janet Krueger, Mara Hester Rendi, Barbara Susnik, Kimberly H. Allison, David G. Hicks, Erinn Downs-Kelly, Michaela L. Tsai, Karen K. Swenson, Tamera J. Lillemoe
Publikováno v:
Journal of Clinical Oncology. 37:e12512-e12512
e12512 Background: HER2 status dictates treatment decisions in breast cancer making the precision and accuracy of laboratory testing essential. While most HER2 testing is straightforward using ASCO-CAP interpretation guidelines, 5% of cases fall into
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf2af214e5513fb5097bbb60008a4c97
https://doi.org/10.1200/jco.2019.37.15_suppl.e12512
https://doi.org/10.1200/jco.2019.37.15_suppl.e12512